查看文章

⁶⁴Cu (half-life, 12.7 h; β⁺, 0.653 MeV [17.4%]; β⁻, 0.579 MeV [39%]) has shown potential as a radioisotope for PET imaging and radiotherapy. ¹¹¹In-diethylenetriaminepentaacetic acid (DTPA)-d-Phe¹-octreotide (OC) was developed for imaging somatostatin-receptor–positive tumors using conventional scintigraphy. With the advantages of PET over conventional scintigraphy, an agent for PET imaging of these tumors is desirable. Here, we show that ⁶⁴Cu-TETA-OC (where TETA is 1,4,8,11-tetraazacyclotetradecane-N,N′,N′′,N′′′-tetraacetic acid) and PET can be used to detect somatostatin-receptor–positive tumors in humans. Eight patients with a history of neuroendocrine tumors (five patients with carcinoid tumors and three patients with islet cell tumors) were imaged by conventional scintigraphy with ¹¹¹In-DTPA-OC (204–233 MBq [5.5–6.3 mCi]) and by PET imaging with ⁶⁴Cu-TETA-OC (111 …